Xeris Biopharma Holdings, Inc./$XERS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Ticker
$XERS
Sector
Primary listing
Employees
435
Headquarters
Website
XERS Metrics
BasicAdvanced
$945M
1,708.76
$0.00
0.97
-
Price and volume
Market cap
$945M
Beta
0.97
52-week high
$10.08
52-week low
$3.81
Average daily volume
2M
Financial strength
Current ratio
2.193
Quick ratio
1.479
Long term debt to equity
1,839.915
Total debt to equity
1,885.441
Interest coverage (TTM)
0.86%
Profitability
EBITDA (TTM)
37.052
Gross margin (TTM)
85.41%
Net profit margin (TTM)
0.19%
Operating margin (TTM)
8.53%
Revenue per employee (TTM)
$670,000
Management effectiveness
Return on assets (TTM)
4.40%
Return on equity (TTM)
-6.96%
Valuation
Price to earnings (TTM)
1,708.762
Price to revenue (TTM)
3.012
Price to book
66.54
Price to tangible book (TTM)
-9.72
Price to free cash flow (TTM)
31.476
Free cash flow yield (TTM)
3.18%
Free cash flow per share (TTM)
0.174
Growth
Revenue change (TTM)
43.72%
Earnings per share change (TTM)
-100.86%
3-year revenue growth (CAGR)
38.33%
3-year earnings per share growth (CAGR)
-83.38%
XERS News
AllArticlesVideos
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
Business Wire·2 weeks ago
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
Business Wire·4 weeks ago
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xeris Biopharma Holdings, Inc. stock?
Xeris Biopharma Holdings, Inc. (XERS) has a market cap of $945M as of March 14, 2026.
What is the P/E ratio for Xeris Biopharma Holdings, Inc. stock?
The price to earnings (P/E) ratio for Xeris Biopharma Holdings, Inc. (XERS) stock is 1708.76 as of March 14, 2026.
Does Xeris Biopharma Holdings, Inc. stock pay dividends?
No, Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next Xeris Biopharma Holdings, Inc. dividend payment date?
Xeris Biopharma Holdings, Inc. (XERS) stock does not pay dividends to its shareholders.
What is the beta indicator for Xeris Biopharma Holdings, Inc.?
Xeris Biopharma Holdings, Inc. (XERS) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.